TX-COGNITIVE-SPACE
6.7.2021 15:02:10 CEST | Business Wire | Press release
Cognitive Space today announced it has been selected to participate in the Amazon Web Services (AWS) Space Accelerator , a business support program for startups seeking to use AWS to help solve the biggest challenges in the space industry. This opportunity will support Cognitive Space efforts to revolutionize satellite operations by bringing the power of artificial intelligence and machine learning to mission operations and collection planning. Cognitive Space provides New Space organizations with sophisticated tools for optimizing revenue and performance yield as their satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005120/en/
New for 2021, the four-week AWS Space Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support in collaboration with Seraphim, one of the world’s leading investment groups focused exclusively on the space industry, who will provide business development and investment guidance.
Cognitive Space will rely on AWS Cloud infrastructure for its own Space-focused software products - including licensed services, underlying platform architecture, development & test environments, and AI/ML training and processing workloads. Cognitive Space will take advantage of AWS services for scalability, cost-effectiveness, security, reliability, and global reach.
“Being one of the few startups accepted into the AWS Space Accelerator is a great honor and we appreciate the confidence AWS has placed in us,” said Scott Herman, CEO of Cognitive Space. “We’re very excited about the mentoring opportunity that the accelerator provides to startups like ours, and we look forward to working closely with AWS and Seraphim as we build our company.” Guy de Carufel, CTO of Cognitive Space, added “We depend on Amazon Web Services to provide high-reliability and scalable infrastructure for the satellite operations services we deliver to our customers and partners, and we are eager to learn more from the AWS experts during the accelerator.”
As one of 10 companies chosen for this opportunity out of a field of approximately 200 startups, Cognitive Space will receive up to $100,000 in AWS Activate credit, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors.
“AWS looks forward to collaborating with our finalists to advance their inspiring vision for transforming how we understand, operate in, and benefit from space,” said Clint Crosier, director of the Aerospace and Satellite business at AWS. “Congratulations to our finalists, who were selected from hundreds of impressive startups from across the global space industry. The cloud is uniquely suited to spur the success of space companies in so many ways, and we are excited to help these companies achieve their biggest goals.”
Proposals were judged on several factors including the innovative and unique nature of the project, the overall value the solution will bring to the space industry, the creative application of AWS to solve problems, and the team’s ability to deliver on its specific mission.
For more information on the AWS Space Accelerator, visit https://seraphim.vc/aws/accelerator/ .
About Cognitive Space
Cognitive Space is developing advanced automation systems for the space industry with a particular focus on the software management of satellite constellations, including mission management, collection planning, communication link management, and modeling & simulation of future capabilities.
Our early focus is on orchestrated collection management for the explosion of new remote sensing constellations - multi-phenomenology, large-fleet constellations of small satellite sensors that offer unprecedented facility monitoring, activity monitoring, and pattern-of-life analysis for national security and commercial organizations with a global monitoring mission.
Cognitive Space is developing an AI-driven solution for near real-time dynamic mission planning for Low Earth Orbit (LEO) Satellites. By 2030, research analysts predict 15-20x growth in deployed satellites in service, from 3000 in 2021 to ~50,000 satellites in orbit. Satellite constellations are increasingly being tasked by government and commercial consumers for use cases including communications, agriculture, environmental protection, meteorology, navigation, national defense, and myriad other commercial, military and governmental use cases.
The Cognitive Space satellite constellation management platform allows operators to reduce command and control lead time, reduce human errors and streamline satellite asset integration. For commercial operators this allows them to maximize service capacity, increase revenue and margin, and optimize performance yield. Cognitive Space’s platform is multi-purpose, serving the needs of the Federal Government, US Department of Defense and commercial enterprises.
More information about Cognitive Space can be found at http://www.cognitivespace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom